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Autosomal recessive congenital ichthyosis (ARCI) repre­
sents a heterogeneous group of rare disorders of coz1r­
nification with 3 major subtypes: harlequin ichthyosis 
(HI), lamellar ichthyosis (LI) and congenital ichthyosi­
form ery throderma (CIE). A 4th subtype has also been 
proposed: pleomorphic ichthyosis (PI), characterized 
by marked skin changes at birth and subsequently mild 
symptoms. In nationwide screenings of suspected cases 
of ARCI in Denmark and Sweden, we identified 132 pa­
tients (age range 0.1–86 years) classified as HI (n = 7), LI 
(n = 70), CIE (n = 17) and PI (n = 38). At birth, a collodion 
membrane or similar severe hyperkeratosis was reported 
in almost all patients with HI and LI, and in nearly half of 
patients with CIE and PI. Persistent ectropion was more 
common in HI (85%) and LI (57%), than in CIE (35%) 
and PI (5%). Anhidrosis was a frequent problem in all 
4 groups (58–100%). A scoring (0–4) of ichthyosis/ery­
thema past infancy showed widely different mean values 
in the subgroups: HI (3.2/3.1), LI (2.4/0.6), CIE (1.8/1.6), 
PI (1.1/0.3). Novel or recurrent mutations were found in 
113 patients: TGM1 (n = 56), NIPAL4 (n = 15), ALOX12B 
(n = 15), ABCA12 (n = 8), ALOXE3 (n = 9), SLC27A4 (n = 5), 
CYP4F22 (n = 3), PNPLA1 (n = 1) and ABHD5 (n = 1). In 
conclusion, by performing a deep phenotyping and gene 
screening, ARCI can be definitely diagnosed in 85% of 
cases in Scandinavia, with a prevalence of 1:100,000 and 
> 8 different aetiologies. Key words: ARCI; congenital 
ichthyosiform erythroderma; harlequin ichthyosis; lamel-
lar ichthyosis; pleomorphic ichthyosis; collodion baby.
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Autosomal recessive congenital ichthyosis (ARCI) 
comprises a group of rare genetic disorders of cornifica-
tion separate from syndromic ichthyoses, epidermolytic 
ichthyosis and the more common ichthyosis vulgaris 
(IV) and X-linked ichthyosis (XLI) which only rarely 
appear at birth (1). The rarest and most severe form of 
ARCI is harlequin ichthyosis (HI) caused by truncating 
mutations in the ABCA12 gene essential for normal 
functioning of the lamellar (Odland) bodies in the upper 
epidermis (2, 3). Lamellar ichthyosis (LI) and congenital 
ichthyosiform erythroderma (CIE) are moderately severe 
forms of ARCI with partially overlapping phenotypes, 
ranging from coarse to fine scaling and mild to severe 
erythema (1). Nine genes1 have so far been implicated 
in the aetiology of LI and CIE, all encoding epidermal 
enzymes and transport proteins, such as transglutaminase 
1, ichthyin and lipoxygenases E3/12B (4–14), essential 
for the formation of a normal stratum corneum (SC) (see 
e.g. 15, 16).
A fourth type of autosomal recessive ichthyosis, inter-
changeably called non-LI/non-CIE (17) or pleomorphic2 
ichthyosis (PI) (18), is characterized by marked cuta-
neous hyperkeratosis at birth followed by spontaneous 
improvement during infancy and subsequently mild 
skin symptoms. The suggested umbrella term PI en-
compasses several distinct conditions: self-improving 
collodion ichthyosis (SICI) (19), ichthyosis prematurity 
syndrome (IPS) (20), bathing-suit ichthyosis (BSI) 
(21), and congenital ichthyosis with fine/mild scaling 
(CIFS) (22). Many of these conditions have a known 
aetiology; for example: TGM1, ALOX12B and ALOXE3 
mutations in SICI and BSI (23, 24), and SLC27A4 
(9q34.11) mutations in IPS (25). Although the latter 
condition is frequently associated with prematurity, 
neonatal asphyxia and atopy, recent evidence suggest 
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that these features are only secondary to the cutaneous 
pathology3, implying that IPS is in fact non-syndromic 
and should be grouped together with other ARCIs, i.e. 
contrary to its current classification (1). 
Although there is some evidence for a genotype–
phenotype correlation in ARCI (1, 27), there has been 
little research into the full spectrum of all clinical and 
genetic variants in patients from a defined geographic 
area. Our study was initiated over a decade ago with 
the explicit aim of examining as many clinically sus-
picious cases of ARCI as possible in 2 neighbouring 
Scandinavian countries, Sweden and Denmark, with 
a combined population of 15 million. In an attempt to 
provide a full overview of the genotypic and pheno-
typic spectra of ARCI in Scandinavia, this paper now 
presents a compilation of our new data, together with 
some previously published results on the same cohort 
of patients (20, 22, 25, 28–34). 
PATIENTS AND METHODS
Patients
This study, which was approved by the ethics committees in 
Uppsala and Odense, involved patients with suspected ARCI 
and neonatal signs of ichthyosis as reported by the patients, 
parents or hospital files. Patients were referred to our diagnostic 
centres for genodermatoses established in the late 90ies at the 
university departments of Dermatology in Uppsala and Odense, 
respectively. All paediatric and dermatological departments in 
Denmark and Sweden, as well as 2 national patient organiza-
tions for ichthyosis, were informed about our study and invited 
to refer patients, who were at least one month old when in-
vestigated by us between 1997 and 2011. The inclusion criteria 
included ichthyosis symptoms at birth and no obvious signs of 
inherent systemic disease. Patients with neonatal erythroderma 
and signs of severe skin barrier failure (e.g. Netherton syndrome 
and epidermolytic ichthyosis) or extracutaneous symptoms con-
sistent with a neuroectodermal syndrome (e.g. Sjögren-Larsson 
syndrome) were not included; neither were families with a 
typical dominant mode of inheritance over several generations. 
After initial clinical screening, 138 patients underwent more 
extensive examinations, at which at least 2 of the authors (AG, 
AB, FB, MV, AV) participated and agreed on the diagnosis, the 
subtype of ARCI (HI, LI, CIE or PI) according to previously 
established criteria (1, 18), and a scoring of ichthyosis and 
erythema severity using a standardized protocol (22), whereby 
all parts of the body (trunk, arms, legs, face, scalp, hands, feet, 
elbows/knees and flexural areas) are first visually scored from 
0 to 4 (none to very severe), followed by multiplying the score 
values of each area with its fractional contribution to the body 
surface using “the rule of 9” (from 0.01 for hands to 0.36 for 
trunk); the sum of these products represents the patient’s whole 
body score with a maximal value of 4.
Four patients (1 Danish and 3 Swedish) were eventually 
excluded from the ARCI group when typical features of ich-
thyosis with confetti (IWC) developed during adolescence and 
DNA analysis confirmed dominant KRT10 mutations (Dr Keith 
Choate, personal communication). Two of these patients were 
previously published as CIE in childhood without known muta-
tion (22, Figs 1e and f). A further 2 patients were excluded when 
DNA analysis unexpectedly confirmed common ichthyosis; one 
patient had recurrent homozygous FLG mutations, and another 
male had a recurrent STS mutation.
The final study group comprised 132 patients from 120 fami-
lies. Seven patients originated from non-Scandinavian countries 
(Iceland, Poland, Middle-East, Cuba and India). Consanguinity 
in the last 3 generations was traced in 6 families. Many of the 
Swedish ARCI patients have been reported previously with 
respect to clinical and ultrastructural findings in the skin, 
and whether TGM1 mutations were present, although without 
providing any mutation details (22). One Swedish family 
with mother and 2 daughters affected with LI was previously 
reported to have novel compound TGM1 mutations, whereas 
the father was a heterozygote carrier (28). Mutation details in 
3 of the patients with HI (32, 33), several of the patients with 
SICI (24), many of the Swedish patients with NIPAL4 mutations 
(31), and all patients with IPS have also been published earlier 
(25, 34), but without providing any ichthyosis and erythema 
scores (now shown in Table SI4).
Venous blood samples were collected from all patients (ex-
cept for the case of one baby with HI where blood was collected 
only from the parents, patient 97 in Table SI4, showing ABCA12 
mutations in both cases). 
Mutation analysis
Genomic DNA was extracted from white blood cells using stan-
dard procedures. The complete coding DNA including intron/
exon boundaries of the following genes were sequenced either 
using Sanger sequencing or next-generation sequencing (NGS): 
TGM1, ABCA12, ALOXE3, ALOX12B, NIPAL4, CYP4F22, 
PNPLA1, CERS3, SLC27A4 and ABHD5. Sequence variants 
found by next NGS were verified by the Sanger technique. 
NGS was performed using Agilent HaloPlex (Agilent Tech-
nologies; Santa Clara, CA, USA) with a custom-designed 
multi-gene panel containing 79 genes (Target Region Size: 
224.563 kbp) associated in inherited skin diseases especially 
keratinization disorders (available on request). The sequencing 
was performed on an Illumina MiSeq® sequencer (illumina; Ann 
Diego, CA, USA) using MiSeq Reagent Kit v2 (2×150 bp). The 
fraction of target bases with at least 50 reads was ~97%. Variant 
calling was performed using GATK (ver. 3.1-1-g07a4bf8) and 
the variants were annotated using ANNOVAR (version date 
2013-11-12).
3In the position paper by Oji et al. (1) the separation of syndromic and 
non-syndromic forms of ichthyosis is discussed; the conclusion was that 
when extracutaneous features, e.g. atopic diathesis, are secondary to a 
faulty skin barrier, such conditions should not be referred to as “syndromic 
ichthyosis”. However, this was not discussed for IPS, which at the time was 
considered a “true” syndrome and thus excluded from ARCI. In a recent 
study of 22 Norwegian patients with IPS, Khnykin et al. (26) conclude 
that all extracutaneous symptoms are probably secondary to a massive 
scaling in utero and a subsequent skin barrier defect. Another argument for 
including IPS among the ARCIs is that at post-infancy the skin phenotype 
is almost indistinguishable from mild ichthyosis. Thus, when a patient with 
undiagnosed IPS is seen for the first time in late childhood (or adulthood) 
and no information is available about the neonatal events, this diagnosis can 
easily be overlooked. Indeed, 9 of the patients in Khnykin et al.’s study were 
not diagnosed until 2–40 years of age, and in an ongoing study of nearly 
700 families with ichthyosis, including ~20 patients with IPS, one-third of 
patients with SLC27A4 mutations were reportedly diagnosed earlier as having 
mild ARCI (JF, unpublished data). 4http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2418
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RESULTS
Clinical subtyping and severity scoring 
Based on the investigators’ consensus decisions, 132 
patients were classified into 4 major clinical subtypes; 
a majority (55%) belonged to the LI group, 27% to PI, 
13% to CIE, and 5% to HI (Table I). Median age at 
examination ranged from 2 years in the HI group to 36 
years in the CIE group, which precluded proper statis-
tical comparisions between the groups. Ichthyosis and 
erythema scores were close to maximum in 3 patients 
with HI with malformed fingers and toes, alopecia, 
tight-sitting ears and abnormal shape of the head. 
Slightly lower scores and less pronounced malforma-
tions were noted in 4 patients with HI-like features, 
2 of whom were described in a previous publication 
(29). The patients with LI and CIE had more variable 
combinations of moderate-severe ichthyosis and none-
moderate erythema scores, whereas those with PI had 
generally low scores. The relationship between ichthyo-
sis and erythema severity in the 4 groups of patients is 
schematically depicted in Fig. S14, with mapping circles 
partially overlapping for LI, CIE and PI, as opposed to 
HI, which is clearly separated from the others. 
Despite the generally low score values observed in 
patients with PI at post-infancy, at least 50% of them 
were born with a collodion or massive hyperkeratosis 
membrane, i.e. consistent with the PI subtypes known 
as SICI, BSI and IPS. A similar frequency of collodion 
at birth was noted in the CIE group (53%), whereas 
75–100% of the LI and HI patients had this neonatal 
phenotype (see Table I). More persistent skin pro-
blems, such as ectropion (35–85%) and palmoplantar 
keratoderma (70–100%), were common in the HI, LI 
and CIE groups, but rarer and milder in the PI group 
(5% and 32%, respectively). Anhidrosis was a common 
problem in all 4 groups (58–100%). 
Thirteen (10%) of the patients (HI = 2; LI =7; CIE = 4) 
used oral retinoids (acitretin or isotretinoin) at the 
time of examination; this probably somewhat redu-
ced the mean ichthyosis scores, but is unlikely to 
have affected the subgrouping of ARCI.
Mutation analysis
Novel or recurrent mutations were found in 113 
(86%) patients; of these, 111 (84%) had bi-allelic 
mutations thus confirming the aetiology of ARCI 
(Tables I, II and Table SI4). Patient no. 45 in Table 
SI4  had only one recurrent TGM1 mutation, but 
complementary analysis disclosed a gene duplica-
tion as culprit. A further patient had a novel ABHD5 
mutation (see Table II), but no signs of liver, mus-
cle or central nervous system (CNS) involvement 
characteristic of Chanarin-Dorfman syndrome (1), 
which probably excludes this gene as the cause of 
the patient’s CIE. 
The mutation details are highlighted in Tables II 
and SI4, and are discussed below and in a footnote 
to Table SI4 in relation to previous reports (4, 5, 8, 
9, 24, 28, 31–45).
Altogether, TGM1 mutations clearly predominate as 
cause of ARCI (n = 56), followed by NIPAL4 (n = 15), 
ALOX12B (n = 15), ALOXE3 (n = 9), ABCA12 (n = 8), 
SLC27A4 (n = 5), CYP4F22 (n = 3), and PNPLA1 
(n = 1). No LIPN and CERS3 mutations were found.
As can be seen from Table I, the aetiology distri-
bution differed among the subgroups: HI was gene-
tically most homogenous, with ABCA12 mutations 
found in 6 of 7 patients. LI was caused by mutations 
in 6 different genes, with TGM1 as the leading cause 
(74%). CIE showed a more scattered aetiology, with 
TGM1 and NIPAL4 mutations each accounting for 
1/4 of the molecularly established diagnoses. In 
contrast, ALOX12B and ALOXE3 mutations predo-
Table I. Clinical and genetic characteristics of 132 Scandinavian 
patients with ARCI classified as: harlequin ichthyosis (HI), lamellar 
ichthyosis (LI), congenital ichthyosiform erythroderma (CIE) or 
pleomorphic ichthyosis (PI). The mean scores of ichthyosis (IS) and 
erythema (ES), and the frequency of certain clinical features are 
shown. “Mutated gene” refers to mutations found in 113 cases; 112 
of these were considered diagnostic (see Table SI4)
ARCI subtype HIa LI CIE PIb
Total patients, n 7 70 17 38
Females, n 3 40 12 23
Danish patients, n 1 21 10 8
Families, n 7 61 17 35
Age, years, median (range) 2 (0.1–39) 31 (1–81) 36 (5–67) 15 (1–79)
Phenotypic score (0–4)
  IS, mean (SD) 3.23 (0.43) 2.43 (0.82) 1.83 (0.90) 1.05 (0.49)
  ES, mean (SD) 3.10 (0.77) 0.60 (0.50) 1.55 (0.61) 0.26 (0.40)
Other features, n (%)
  Collodion or similar 7 (100) 52 (74) 9 (53) 19 (50)
  Ectropion 6 (85) 40 (57) 6 (35) 2 (5)
  Keratoderma 7 (100) 57 (81) 12 (70) 12 (32)
  Anhidrosis 7 (100) 67 (96) 14 (82) 22 (58)
  Retinoid therapyc 2 (29) 7 (10) 4 (23) 0
Mutated gene, n 
  TGM1 0 48 3 5
  NIPAL4 0 10 3 2
  ALOX12B 0 3 2 10
  ALOXE3 0 1 0 8
  ABCA12 6 0 2 0
  SCL27A4 0 0 0 5
  CYP4F22 0 2 1 0
  PNPLA1 0 1 0 0
  ABHD5 0 0 (1)d 0
aIncludes 3 typical HI and 4 HI-like cases. Two babies died within 5 weeks of 
age. bPI includes 18 patients with self-improving collodion ichthyosis (TGM1 
(n = 4), ALOX12B (n = 9) and ALOXE3 (n = 4)), 14 patients with congenital 
ichthyosis with fine scaling (ALOX12B (n = 1), ALOXE3 (n = 4), NIPAL4 (n = 1) 
and ABCA12 (n = 1)), 5 patients with ichthyosis prematurity syndrome due to 
SCL27A4 mutations, and one patient with bathing-suit ichthyosis due to TGM1 
mutations. cRefers to ongoing oral acitretin or isotretinoin therapy at the time 
of examination. dThis patient was excluded from Table SI4, but is included in 
Table II (novel mutation). She has CIE but no extracutaneous signs of Chanarin-
Dorfman syndrome (see text). Whether or not her mono-allelic ABHD5 mutation 
contributes to the pathogenisis of CIE cannot yet be determined.
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minated the PI group, especially in patients subtyped as 
SICI or CIFS without proven birth as collodion baby, 
whereas SCL27A4 mutations were restricted to patients 
with IPS. Lastly, mutations in CYP4F22, PNPLA1 and 
(ABHD5) were associated with LI or CIE.
DISCUSSION
This study, which describes the phenotypic and geno-
typic characteristics of an ethnically not completely 
homogenous cohort of 132 patients with ARCI living in 
2 neighbouring countries (Sweden, population 9.5 mil-
lion, and Denmark, population 5.5 million), represents 
one of the largest published so far. In our capacity as 
the national referral centres for ichthyosis in Denmark 
and Sweden, working in close alliance with existing 
patient organizations, we have reason to believe that 
our cohort represents > 90% of all patients with ARCI 
living in this region, yielding a prevalence figure of 
approximately 1:100,000 in the period 1997 to 2010. 
This figure is close to the estimates in many other 
countries, including a recent study from Spain (46).
Some notable features of our study are that: (i) all 
patients underwent a deep phenotyping and clinical sub-
grouping of ARCI (see Table I); (ii) we used the same 
area-related scoring method for scaling and erythema 
as in a previous study of Swedish patients belonging to 
the same cohort (22); (iii) the scoring, although not yet 
validated, was performed by the same investigators and 
at an age (> 1 year) when the patients’ skin phenotype 
is mostly stable (many patients were followed by us for 
decades), and (iv) the genetic screening, which conti-
nued over a period when several new ARCI genes and 
improved DNA technologies appeared, unravelled the 
aetiology in approximately 85% of patients, i.e. higher 
than in many previous studies using a more restricted 
definition of ARCI (for review see (27)).
Some of the phenotypic data have already been dis-
cussed under Results. A pertinent finding is the high 
frequency of anhidrosis also in the PI group (58%), 
despite a barely visible ichthyosis in many cases. This 
may bring into question the current hypothesis about 
the pathogenesis of anhidrosis, i.e. that a marked ich-
thyosis will obstruct the sweat ducts and thus prevent 
sweat from reaching the skin surface. 
Some of the DNA results deserve special comments. 
As in previous studies from other countries (e.g. 27, 41, 
47), we found TGM1 mutations to be the leading cause 
of ARCI in Scandinavia, with 29 different mutations 
represented, 8 of which are novel. The point mutation 
c.877-2A>G was identified in 14% of alleles associated 
with LI/CIE, mainly in the Swedish patients. This muta-
tion has also been described from several other countries 
(37, 38, 40, 41, 48–53) and is reported as a founder 
mutation in Norway (49), located close to Sweden. The 
p.Ser358Arg mutation was originally identified in a Swe-
dish family (28) and there is no report of this mutation 
outside Sweden and Norway (unpublished data), which 
suggests a local founder mutation. The reason for the 
lower frequency of TGM1 mutations in Danish (22%) 
compared with Swedish (50%) patients is not known, 
but a lack of founder effect is a possible explanation. 
Although TGM1 mutations were primarily associated 
with the LI phenotype, their rare occurrence also in 
the CIE group and in occasional patients with BSI and 
SICI in the PI group is noteworthy. The association of 
TGM1 mutations with many different skin phenotypes 
is further illustrated by the previous finding of 2 dif-
ferent electron microscopy (EM) patterns in SC; type 
1 (lipid droplets) and type 2 (cholesterol clefts) (22, 
35, 49, 54). In contrast, NIPAL4 mutations are often 
associated with EM type 3 (bizarre membranes) (31) 
and can cause LI and CIE, but hardly any other ARCI 
phenotype. NIPAL4 mutations were the second most 
common cause of ARCI in Denmark (16%) and the 
third most common cause in Sweden (8%). 
ALOX12B mutations are predominantly associated 
with the SICI subtype of PI (24, 55) and were more 
frequent in Swedish (13%) than in Danish (8%) patients, 
whereas ALOXE3 mutations were associated with both 
Table II. Novel mutations detected in the investigated ARCI genes 
of the Scandinavian patientsa (For further information about allele 
pairs, clinical details, etc., see Table SI4)
Mutation Consequence
TGM1  
  c.918C>G p.Asp306Glu
  c.1094A>G p.Tyr365Cys
  c.1163T>C p.Leu388Pro
  c.1389A>T p.Gln463His
  c.1438A>T p.Ile480Phe
  c.1686_1695delCCACGGCAGC p.His563fs
  c.1927+1G>A splice site (intron 12)
  c.2150T>G p.Leu717Arg
ALOXE3  
  c.353-1G>C splice site (intron 3)
ABCA12  
  c.1002_1004delAACinsT p.Thr335fs
  c.1782G>A p.Glu594Glub
  c.4554G>A p.Trp1518Termc
  c.4896del G p.Ser1633fs
  c.6263T>C p.Leu2088Pro
  c.7137delG p.Met2380fs
  c.7412G>A p.Gly2471Glu
CYP4F22  
  c.59dupG p.Ile21fs
  c.667C>T p.Gln223Term
  c.727C>T p.Arg243Cys
ABHD5  
  c.341G>T (mono-alleic) p.Arg114Leu (carrier?)d
PNPLA1  
  c.775+3A>T splice site (intron 5)e
aThese mutations are either not in ExAC/dbSNP or have a minor allele 
frequency < 0.008. bSilent mutation affecting a splice site in exon 14. 
cp.Trp1518Term as a consequence of c.4553G>A is previously reported. dNo 
mutation was identified in the second allele by sequencing of the coding regions 
or by deletion/duplication analysis. eImmunohistochemistry showed deficient 
epidermal expression of the protein (result not shown).
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LI and PI, and were altogether less common; although 
not as rare as for example in Asia (56). 
ABCA12 mutations, previously reported in 3 of the 
Swedish patients with HI (32, 33), were now identified 
in 3 additional HI-like patients carrying 3 novel muta-
tions (see Table II). Our finding of ABCA12 mutations 
also in 2 patients with CIE corroborates previous sug-
gestions that different types of ABCA12 mutations may 
produce widely different phenotypes (7, 57). 
Three patients had mutations in CYP4F22 and one in 
PNLPA1, in all cases associated with mild to moderate 
LI/CIE. No new SCL27A4 mutations causing IPS were 
identified in this study. The mutation details of the 5 in-
cluded patients from Sweden and Denmark were discus-
sed previously (25, 34), albeit then without providing any 
score data. A clustering of IPS in northern Sweden and 
Norway motivates its inclusion in the differential diag-
nosis of ARCI in Scandinavia, especially when exami-
ning adult cases with mild ichthyosis and no knowledge 
is available about the perinatal events (see footnote 3). It 
is also important to recognize other types of ichthyosis, 
such as IWC, IV and XLI, which especially in children 
may mimic ARCI, as illustrated by 6 excluded cases in 
our study (see Materials and Methods). 
In conclusion, this study highlights how a deep 
phenotyping (clinical subtyping plus severity scoring 
of ichthyosis and erythema) can help clinicians and 
geneticists to preliminarily classify a case of ARCI 
and hence to decide which candidate genes should be 
prioritized in the search for a molecular diagnosis, i.e. 
the very basis for a proper genetic counselling and, 
presumably in the future, for a correct therapy. It is 
noteworthy that, despite our extensive screening of 
10 genes, we failed to establish a molecular diagnosis 
in approximately 15% of the patients (mainly in those 
with the CIFS subtype of PI). This strongly suggests 
that new aetiologies remain to be discovered5. It is 
hoped that recent progress in NGS methods and gene 
panels will open up the possibility of rapid diagnostic 
analysis of ichthyosis by including a large number of 
ARCI-related genes. 
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